newsfilter
← Latest News
Business Wire·

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster presentations